

Figure S1. Forest plot of comparison: molecular-targeted therapy alone/plus chemotherapy versus chemotherapy alone/placebo. Main analyses; outcome: Overall Survival. Analysis of subgroups by type of molecular therapy (anti-VEGFR and anti-MET).





Figure S2. Forest plot of comparison: molecular-targeted therapy alone/plus chemotherapy versus chemotherapy alone/placebo. Main analyses; outcome: Progression Free Survival. Analysis of subgroups by type of molecular therapy (anti-VEGFR and anti-MET).

Table S1. Patient characteristics of studies included in the last Cochrane review.

| Author, Year, Acronym | Nr Total pts (EXP/CTR) | Treatment Line (%) | Primary Endpoint | Setting | Molecular Target | EXP Arm | CTR Arm | Tumor Stage (%) | Tumor Site (%) |
|------------------------------|------------------------|--------------------|--------------------|---------|------------------|--|-------------------------------|-----------------|-------------------------------------|
| Bang [12], 2010 ToGA | 594(294/290) | I II | OS | Adj | HER-2 | Trastuzuma b + fluoropyrimidine + cisplatin | Fluoropyrimidine + cisplatin | III IV | Stomach GEJ |
| Eatock {76}, 2013 | 171 (56 + 59/56) | I II | PFS | Adj | VEGF-A | Trebananib + CX | CX | IV | Stomach GEJ Distal oesophagus |
| Hecht [58], 2013 | 545 (272 /273) | I II | OS | Adj | HER-2 | Lapatinib + XELOX | Placebo+ XELOX | III IV | Stomach GEJ Oesophagus |
| Iveson [77], 2014 | 121 (42 + 40/39) | | OS | Adj | HGF | rilotumuma b + ECX | Placebo + ECX | III IV | Stomach GEJ |
| Koizumi [78], 2013 | 93 (46 /47) | I | PFS | Adj | VEGFR-2 | Orantinib + S-1/CDDP | S-1/CDDP | III | Stomach |
| Lordick [61], 2013 EXPAND | 904 (455 / 449) | I II | PFS | Adj | EGFR | Cetuximab+ capecitabine and cisplatin | capecitabine and cisplatin | IV III | Stomach GEJ |
| Ohtsu [40], 2011 AVAGAST | 774 (387 /387) | I | OS | Adj | VEGF | bevacizuma b + capecitabine and cisplatin/FU | capecitabine and cisplatin/FU | III IV | Stomach GEJ |
| Rao [79], 2010 | 72 (36/36) | I | Objective response | Adj | EGFR | Matuzumab + ECX | ECX | IV | Stomach GEJ Distal oesophagus |
| Shen [80], 2015 AVATAR Study | 202 (100 /102) | I | OS | Adj | VEGFR | Bevacizuma b + CX | CX | III IV | Stomach GEJ |
| Waddell [55], 2013 REAL3 | 553(278/275) | I | OS | Adj | HER-1 | Panitumuma b + EOC | EOC | III IV | Stomach EGJ Oesophagus |
| Zhang [81], 2014 | 56 (30/26) | I II | OS | Adj | EGFR | Cetuximab + S-1 and oxaliplatin | S-1 and oxaliplatin | III IV | Stomach |

Pts: patients; CX: cisplatin and capecitabine; XELOX: Capecitabine+ Oxaliplatin; ECX: epirubicin, cisplatin, and capecitabine; S-1: fluoropyrimidine; CDDP: cisplatin; EOC: epirubicin and oxaliplatin and capecitabine.